Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Javle, M. [1 ]
Fogelman, D. [1 ]
Kaseb, A. [1 ]
Varadhachary, G. [1 ]
Wolff, R. [1 ]
Abbruzzese, J. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72262-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [1] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
  • [2] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [3] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [4] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [5] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [6] Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study.
    Van Laethem, JL
    Polus, M
    Marechal, R
    Demols, A
    Gay, F
    Marijken, M
    Hendlisz, A
    Peeters, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 343S - 343S
  • [7] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced Hematologic malignancies
    Yee, K
    O'Brien, S
    Wierda, W
    Thomas, D
    Kurzrock, R
    Fayad, L
    Hagemeister, F
    Goy, A
    Cortes, J
    Prestifilippo, J
    Szatrowski, T
    Kantarjian, H
    Giles, F
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S35 - S35
  • [8] Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer - dose finding study
    Joka, M.
    Pustowka, A.
    Alberter, B.
    Hosius, C.
    May, C.
    Decroix, L.
    Bruns, C.
    ONKOLOGIE, 2010, 33 : 80 - 81
  • [9] Activity of mTOR-Inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
    Behlendorf, T.
    Voigt, W.
    Mueller, T.
    Jordan, K.
    Arnold, D.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
    Kim, Jung Hoon
    Lee, Sang-Cheol
    Oh, Sung Yong
    Song, Seo-Young
    Lee, Namsu
    Nam, Eun Mi
    Lee, Soonil
    Hwang, In Gyu
    Lee, Hyo Rak
    Lee, Kyu Taek
    Bae, Sang-Byung
    Kim, Han Jo
    Jang, Joung Soon
    Lim, Do Hyoung
    Lee, Hyun Woo
    Kang, Seok Yun
    Kang, Jung Hun
    CANCER COMMUNICATIONS, 2018, 38
12345